Clinical trials: HER2-Positive Breast Carcinoma, open to volunteers
HER2-positive Breast Cancer
Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer
This study is a one-arm, open, phase II clinical study, and the study subjects are locally advanced and inflammatoryPatients with sexual or early HER2-positive breast cancer entered the trial period after signing informed…
- Trial name
- NCT04481932
- Testing
- Trastuzumab combined with Pyrotinib and chemotherapy
- Where
- China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Peking University
HER2-positive Breast Cancer
Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer
This study is to explore the markers in early prediction of the efficacy of pre-operative pertuzumab plus trastuzumab (PH) combined with chemotherapy for early stage or locally advanced human epidermal growth factor receptor-2…
- Trial name
- PHC-BC (NCT04281641)
- Testing
- TCHP
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Fudan University
Breast Cancer, Triple Negative Breast Cancer
Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy
This study evaluates whether SLNB can safely be omitted in breast cancer patients with HER2+ or TN tumors who achieve a radiological complete response on MRI after neoadjuvant systemic therapy
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, HER2-positive Breast Cancer, Sentinel Lymph Node
- Trial name
- ASICS (NCT04225858)
- Testing
- Omission of sentinel lymph node biopsy
- Volunteers
- 340 people
- Sponsor
- The Netherlands Cancer Institute
HER2-positive Breast Cancer
Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer
This phase II trial aims to study the efficacy and safety of adjuvant Pyrotinib plus trastuzumab in patients with tumors <8mm, node-negative, HER2-positive breast cancer.
- Trial name
- SHERO (NCT04158856)
- Testing
- Pyrotinib, Trastuzumab
- Volunteers
- 60 people
- Sponsor
- xuexin he